series-a
Stage
About
Sanmirna Therapeutics is developing microRNA-based therapies targeting leukemia stem cells in Acute Myeloid Leukemia (AML) to overcome treatment resistance, with a lead asset Miristen™ currently in Phase 1 clinical trials in partnership with City of Hope.
Explore Sanmirna Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.